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Abstract
Nucleic acid aptamers have been developed as high-affinity ligands that may act as antagonists of disease-associated
proteins. Aptamers are non immunogenic and characterised by high specificity and low toxicity thus representing a valid
alternative to antibodies or soluble ligand receptor traps/decoys to target specific cancer cell surface proteins in clinical
diagnosis and therapy. The epidermal growth factor receptor (EGFR) has been implicated in the development of a wide
range of human cancers including breast, glioma and lung. The observation that its inhibition can interfere with the growth
of such tumors has led to the design of new drugs including monoclonal antibodies and tyrosine kinase inhibitors currently
used in clinic. However, some of these molecules can result in toxicity and acquired resistance, hence the need to develop
novel kinds of EGFR-targeting drugs with high specificity and low toxicity. Here we generated, by a cell-Systematic Evolution
of Ligands by EXponential enrichment (SELEX) approach, a nuclease resistant RNA-aptamer that specifically binds to EGFR
with a binding constant of 10 nM. When applied to EGFR-expressing cancer cells the aptamer inhibits EGFR-mediated signal
pathways causing selective cell death. Furthermore, at low doses it induces apoptosis even of cells that are resistant to the
most frequently used EGFR-inhibitors, such as gefitinib and cetuximab, and inhibits tumor growth in a mouse xenograft
model of human non-small-cell lung cancer (NSCLC). Interestingly, combined treatment with cetuximab and the aptamer
shows clear synergy in inducing apoptosis in vitro and in vivo. In conclusion, we demonstrate that this neutralizing RNA-
aptamer is a promising bio-molecule that can be developed as a more effective alternative to the repertoire of already
existing EGFR-inhibitors.
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Introduction
The EGFR/ErbB family of receptor tyrosine kinases (RTK)
comprises four members: EGFR (also known as HER1 or ErbB1),
ErbB2 (Neu, HER2), ErbB3 (HER3) and ErbB4 (HER4),
containing an extracellular ligand binding region, a single
membrane-spanning region and an intracellular tyrosine-kinase-
containing domain. Unlike the rest of the ErbB family, ErbB3 lacks
tyrosine kinase activity and ErbB2 has no known ligand. Epidermal
growth factor (EGF) and transforming growth factor-a bind directly
only to EGFR, whereas neuregulins (also known as heregulins) are
specific for ErbB3 and ErbB4 [1,2]. Ligand-induced activation of
EGFR by dimerization mediates multiple intracellular pathways
that inhibit apoptosis and promote survival and proliferation [3,4].
Deregulation of EGFR by over-expression or constitutive
activation promotes tumor processes including angiogenesis and
metastasis and is associated with poor prognosis in many human
malignancies including glioma, lung and breast cancer [1,2].
The prevalence of this receptor in well-established cancers has
elicited several studies and discoveries leading to the generation of
multiple Food and Drug Administration (FDA) approved agents
including the monoclonal antibodies (as cetuximab and panitu-
mumab for the treatment of colorectal cancer, NSCLC, and
squamous cell carcinoma of the head and neck) that bind to the
extracellular domain of EGFR, and small-molecule inhibitors (as
gefitinib, erlotinib and lapatinib for the treatment of NSCLC,
breast and pancreas cancers) that compete with ATP for binding
to the tyrosine kinase domain of the receptor [2,5–8].
The treatment of tumor cells with these agents affects many of
the intracellular pathways that are essential for cancer develop-
ment and progression. However, patients receiving these treat-
ments often show primary or acquired resistance to the inhibitors
[9–11]. Thus, new strategies to overcome tyrosine kinase inhibitors
(TKI) resistance are under active exploration and there is the
urgent need to design new EGFR-targeting drugs for a more
specific and selective tumor therapy.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24071An emerging new class of targeted therapeutic molecules against
RTKs is composed of nucleic acid-based aptamers. They are short
structured single-stranded RNA or DNA ligands that bind with
high selectivity and sensitivity, due to their specific three-
dimensional shapes, to their target molecules. Aptamers possess
many advantages over proteins as therapeutic reagents, including
low cost, convenient synthesis and modification with high batch
fidelity, no immunogenicity, rapid tissue penetration and long-
term stability [12–14]. Further, in the last years, aptamers
targeting cell surface proteins are being explored as promising
delivery vehicles to target a distinct disease or tissue in a cell-type
specific manner [13,15,16]. The list of inhibitory aptamers for
therapeutic use is growing rapidly and one aptamer (Macugen)
against the vascular endothelial growth factor was approved by
FDA for the treatment of age-related macular degeneration [17].
To date, unmodified RNA-aptamers have been selected against
the purified extracellular domain of EGFR and then used for gold-
nanoparticles delivery to cancer cells [18] or, in a surface-
immobilized form, to capture EGFR-expressing glioma cells [19].
These studies offer solid proof-of-concept for delivery strategies
and for cancer cells isolation approaches, even though no direct
inhibition of EGFR has been shown. More recently, a 29-fluoro-
modified RNA aptamer against recombinant human EGFR
protein has been described [20]. The aptamer blocks EGF-
dependent receptor autophosphorylation in vitro but has not been
evaluated in animals.
Herein, we have generated a nuclease-resistant RNA-aptamer
(named CL4) able to bind at high affinity to EGFR on the surface
of different cancer cells and to block EGFR downstream signaling
via inhibition of either EGFR homodimers and heterodimers with
cognate ErbB2 or ErbB3, thus irrespective of the ligand that
causes receptors dimerization. It induces selective cell death in vitro
and in vivo, thus revealing an EGFR-drug candidate with
promising translational potential.
Results
CL4 aptamer specifically interacts with EGFR
By using differential whole-cell SELEX on human NSCLC we
identified a set of five families of sequence related 29-fluoro
pyrimidines (29-F Py) RNA-aptamers that distinguish A549 cells
(resistant to cell death induced by TRAIL, cisplatin and paclytaxel)
from the more sensitive H460 cells. CL4 full-length (FL), the best
candidate aptamer from this selection, efficiently binds to A549 cells
with an apparent dissociation constant (Kd) value of 46 nM (not
shown). Based on the predicted secondary structure of the 92mer
original molecule, we designed a shorter aptamer of 39mer (herein
indicated as CL4) containing the functional site of CL4 FL (Fig. 1A)
that preserveshighbindingaffinitytoA549cellswitha Kdof38 nM
and discriminates them from H460 cells (not shown). Further, using
a phospho-RTK array analysis to identify functional targets of CL4
provided us convincing evidence that the target of the aptamer
could likely be EGFR and/or ErbB3 (Fig. S1).
To definitely identify the cellular target of CL4 we first
performed a filter binding analysis with the soluble extracellular
domain of human EGFR and ErbB3 (indicated as EC-EGFR and
EC-ErbB3, respectively) as targets, that confirmed a strong affinity
of CL4 for EC-EGFR (Kd value of 10 nM, Fig. 1B) while no
appreciable CL4 binding was observed to EC-ErbB3 (Fig. 1C).
Further, CL4 shows comparable binding for both the disulfide-
linked EGFR dimer and for the reduced monomer (Fig. 1C).
Accordingly, binding analyses on NIH3T3 cells stably trans-
fected with human EGFR (NIH/EGFR) that express a very high
level of EGFR (Fig. 2A) showed that CL4 bound to NIH/EGFR
but not to parental cells (Fig. 2B) with an apparent Kd value of
60 nM (not shown). Conversely, binding to A549 cells was
decreased by interfering with EGFR expression and by high
concentration of EGF (Fig. 2C,D). Consistently with its ability to
specifically bind to membrane-bound as well as to the soluble
ectodomain of EGFR, we found that CL4 binding to A549 cells
was competed by EC-EGFR but not by EC-ErbB3 (Fig. 2E).
The specific interaction of CL4 with EGFR on cell surface was
further analyzed by affinity purification on streptavidin coated
beads of extracts from A549 cells treated with biotin-labeled CL4
followed by immunoblotting with anti-EGFR antibodies. As
shown, CL4 specifically interacts with EGFR on cell surface
whereas no binding was obtained with CL4sc, the scrambled 29F-
Py RNA used as a negative control (Fig. 2F).
Further, we determined binding of CL4 on stable tumor derived
cell lines that differently express EGFR family members (EGFR,
ErbB2, ErbB3, or ErbB4). As expected, CL4 binding was detected
solelyoncellsthatexpresshighlevelofEGFR,eitherinthepresence
or in the absence of other members of that family (Fig. S2).
Taken together, these results indicate that the CL4 aptamer
recognizes specifically and at high affinity the EGFR in its
physiological context on the cell surface as well as the purified
extracellular domain of the receptor both as monomer or dimer.
CL4 inhibits EGFR-mediated signaling pathways
Ligand binding to EGFR induces the formation of receptor
homo- and heterodimers with three other ErbB family members
resulting in kinase activation, tyrosine-phosphorylation and
intracellular signaling. Among the EGF family of growth factors,
binding of EGF to EGFR preferentially induces the formation of
EGFR-EGFR and EGFR-ErbB2 complexes and, at a less extent,
of EGFR-ErbB3 [1,21].
Thus, we determined in A549 cells whether CL4 could affect
EGFR activation following EGF stimulation. CL4 treatment
drastically reduced the tyrosine-phosphorylation of EGFR in a
time-dependent manner reaching 70% inhibition at 30 min of
EGF treatment, whereas no effect was observed in the presence of
CL4sc scrambled sequence (Fig. 3A).
Among the main intracellular effectors of EGFR that mediate
induction of cell proliferation and resistance to apoptosis are
extracellular-signal regulated kinase 1/2 (ERK1/2), AKT and
signal transducers and activator of transcription (STAT) proteins
[1,4]. As shown in figure 3A, the phosphorylation of ERK1/2 is
strongly induced by EGF with a peak at 5 min and rapidly
declines. CL4 treatment reduced the extent of phospho-ERK1/2
at all time points with a maximum of inhibition at 30 min (50%
inhibition as compared to CL4sc).
EGF binding to EGFR results as well in the activation of the
anti-apoptotic STAT3 protein [1,22,23]. We thus looked whether,
as a consequence of EGFR inhibition, CL4 could interfere with
STAT3 activation. Treatment with CL4 for 15 min was sufficient
to inhibit tyrosine-phosphorylation close to the basal level thus
showing an inhibition kinetic more rapid for STAT3 than for
ERK1/2 (Fig. 3A). Further, in agreement with its ability to bind
Calu1 and A431 cells, CL4 strongly inhibited EGF-induced
activation of EGFR and STAT3 in these cells (Fig. 3B,C).
On the other hand, even though the phosphorylation of AKT is
strongly induced by 5 min-EGF stimulation and rapidly declines,
200 nM-CL4 treatment had no appreciable effect on that kinase
and the levels of phospho-AKT Ser473 remained comparable to
the control up to 30 min of treatment (Fig. 3A). The same result
was obtained looking at phospho-AKT Thr308 (not shown).
Increasing the CL4 concentrations up to 500 nM was as well
ineffective in inhibiting phospho-AKT levels (unpublished data). A
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preferentially inhibits the EGFR-EGFR homodimers that primar-
ily occur following EGF stimulation. Indeed, the EGFR-
dependent activation of phosphoinositide 3-kinase (PI3K)/AKT
occurs mainly through dimerization of EGFR with ErbB3 since
PI3K docking sites are absent on EGFR and ErbB2, whereas, are
highly prevalent on ErbB3 [1,4].
We thus wondered whether, as a result of its binding to EGFR,
CL4 could interfere with ligand-dependent EGFR/ErbB2 hetero-
dimerization in SKBr3 cells that, differently from the analysed
NSCLC and A431 cells, express very high levels of ErbB2 (Fig.
S2A,C). As shown in Fig. 3D, CL4-treatment resulted in a strong
reduction of ligand-induced phosphorylation of ErbB2 that
reached the basal, un-stimulated, levels.
EGFR activation may also occur upon heregulin (Hrg) binding
to ErbB3 and consequent heterodimerization of ErbB3 with
EGFR [1,21]. Thus, in order to investigate whether CL4 may
interfere as well with EGFR/ErbB3 heterodimerization, we looked
at the effect of the aptamer on the Hrg-mediated signal pathways.
To this aim, A549 and Calu1 cells were stimulated with Hrg in the
presence of CL4 or CL4sc and the tyrosine-phosphorylation of
ErbB3 and EGFR was determined by immunoblotting (Fig. 4A,B).
The low intensity of phospho-EGFR after Hrg stimulation likely
reflects the low levels of ErbB3 in these cells (Fig. S2A) and
suggests that Hrg induces formation of EGFR-ErbB3 heterodi-
mers poorly, in agreement with previously published findings [24].
In the presence of CL4, phosphorylation levels of both ErbB3
and EGFR are reduced to the un-stimulated levels (Fig. 4A,B).
Further, CL4 reduced of about 50%, as compared to CL4sc, the
Hrg-dependent activation of ERK1/2 and AKT in both the
analyzed cell lines (Fig. 4A,B), thus indicating that the action of
CL4 on AKT may depend on the specific dimer formed.
The above results indicate that the binding of CL4 to cell-
surface exposed EGFR results in blocking of the receptor
activation, both if induced by homodimerization and hetero-
dimerization with either ErbB2 or ErbB3, thus in turn hampering
the EGFR-dependent downstream signaling pathways. In all cases,
inhibition is mediated by specific recognition of EGFR since CL4
Figure 1. The anti-EGFR CL4 aptamer. (A) Secondary structure of CL4 Full Length predicted by using MFOLD software version 3.1. The structure
of CL4 (nucleotides from 42 to 81) is shown in red. (B) Binding isotherm for CL4:EC-EGFR complexes. Kd value was derived by fitting bound CL4 versus
the protein concentration to the equation Y=BmaxX/(Kd+X), where Bmax is the extrapolated maximal amount of RNA:protein complex bound. The
specific binding was determined by subtracting the background values obtained with CL4sc from the values obtained with CL4. (C) EC-EGFR or EC-
ErbB3 (20 and 40 nM, with and without DTT treatment) were incubated with 1 nM CL4 and radiolabeled protein-bound RNA was collected by
nitrocellulose filters and quantified.
doi:10.1371/journal.pone.0024071.g001
Aptamer Inhibition of EGFR
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24071Figure 2. CL4 specifically interacts with EGFR. (A) Lysates from NIH3T3 or NIH/EGFR cells were immunoblotted with anti-EGFR antibodies.
atubulin was used as an internal control. (B) Binding of radiolabeled CL4 on NIH3T3 or NIH/EGFR. (C) Lysates from A549 cells following 72 h-
transfection with a specific EGFR shRNA (shRNAEGFR) or a non-related shRNA (shRNActrl) were immunoblotted with anti-EGFR antibodies. atubulin
was used as an internal control. Values below the blot indicate signal levels relative to control non transfected, arbitrarily set to 1 (labeled with
asterisk). Intensity of bands has been calculated using the NIH Image Program on at least two different expositions to assure the linearity of each
acquisition. (D) Binding of 100 nM radiolabeled CL4 on A549 cells in the absence or in the presence of 1 mM EGF or on A549 cells following 72 h-
transfection with shRNAEGFR or shRNActrl. (E) Binding of 100 nM radiolabeled CL4, prior incubated with 300 nM EC-EGFR or EC-ErbB3 for 15 min at
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low or undetectable levels of EGFR (Fig. S2A,C).
CL4 strongly induces apoptosis in EGFR-positive cells
The identification of an aptamer that specifically binds and
inhibits EGFR, hampering the anti-apoptotic STAT3 pathway,
raises the obvious question of whether this aptamer may interfere
with survival of target cells. The 24 h-treatment of A549, Calu1
and A431 cells with CL4 strongly inhibited cell viability that was
reduced of about 60% by comparison with cells untreated or
treated with CL4sc. Accordingly with the inability of CL4 to
efficiently bind to H460 cells, it did not affect cell viability (Fig.
S3A).
Moreover, in our experimental condition no additive effect on
A549 cell viability was observed by combining CL4 treatment with
TRAIL, cisplatin or paclytaxel (Fig. S3B).
In order to dissect the molecular mechanism of CL4 induced
cell viability reduction, we analyzed apoptosis in A549 cells
following aptamer treatment. Remarkably, we found that the
percentage of apoptotic cells was about 30% after 24 h-CL4
treatment reaching 40% after 48 h. No effect was observed in the
presence of the negative control (Fig. 5A). Next, we examined
whether CL4 treatment activated the executioner caspase-3 and
the initiator caspases-8 and 9. As shown, treatment of A549 cells
with CL4 resulted in a strong caspase-3 (Fig. 5B–D), caspase-8
(Fig. 5E,F) and caspase-9 (Fig. 5E) cleavage. Cleavage of Poly
(ADP-ribose) polymerase (PARP) also correlated with caspase-3
activation (Fig. 5D). High concentration of TRAIL (200 ng/ml)
was used as a positive control of caspases activation (Fig. 5D–F).
These data indicate that CL4 interferes with cell proliferation by
activating apoptosis, likely by down regulating STAT3 function or
that of other members of the same protein family.
CL4 inhibits tumor growth
We next assessed the efficiency of CL4 for its ability to inhibit
cell proliferation in vitro and limit tumor growth in vivo. As shown,
treating A549 cells with CL4 for 24 and 48 h completely blocks
[
3H]-thymidine incorporation (Fig. 6A). In addition, in A549-
mouse xenografts a pronounced reduction in tumor volume was
observed in the presence of CL4-treatment, leading at day 16 to
57% inhibition with respect to CL4sc control (Fig. 6B). According
with the effects observed in vitro, CL4-treatment of xenograft
tumors decreases the extent of EGFR tyrosine phosphorylation
and activates caspase- 3 and -8 (Fig. 6C,D).
As a next step, we compared the inhibition effect on cell viability
of the CL4 to that of two commercially available EGFR inhibitors
that are currently in clinical use as anticancer therapeutics,
gefitinib and cetuximab. In dose-dependent experiments (gefitinib,
0.1–10 mM and cetuximab, 0.05–1 mM), A549 cells resulted
resistant at any concentration, even a high concentration of the
above inhibitors ([25,26], and our unpublished data). Interestingly,
cells are highly sensitive to a 200 nM-final concentration CL4-
treatment (Fig. 6E) and the same effect was observed on Calu1 and
A431 (not shown). Further, as shown, the combined treatment of
CL4 with cetuximab inhibited A549 cell viability more effectively
than the treatment with each single agent alone, thus showing
additive interactions. On the contrary, CL4 effectiveness was not
improved when administered in combination with gefitinib. Most
importantly, the synergy between CL4 and cetuximab was
confirmed in vivo in mice xenografted with A549 cells (Fig. 6F,G).
Indeed, the combination of CL4 and cetuximab decreased the
number of proliferating Ki-67-positive cells and increased the
number of apoptotic cells stained positively for terminal deox-
ynucleotidyl transferase mediated dUTP nick end labeling
(TUNEL) more efficiently than the treatment of each inhibitor
alone. Whether the aptamer and the antibody bind to different
epitopes on the receptor, remain to be determined.
Discussion
Here we developed and characterized a 29-F Py RNA aptamer,
named CL4, capable of binding and inhibiting EGFR.
We show that CL4 binds EGFR on tumor cell surface as well as
the soluble extracellular domain of the receptor with a Kd of
10 nM, while it does not bind to the other members of the ErbB
family, ErbB2, ErbB3 or ErbB4. It specifically binds to any cell
types provided that EGFR is expressed on cell surface and inhibits
both EGFR activation and EGFR-mediated signal pathways.
It has been clearly shown that EGFR monomers can pair and
form heterodimers with other members of the ErbB family
[4,27,28]. The presence of these heterodimers renders several
EGFR inhibitors poorly efficient as therapeutics [29]. By binding
either the EGFR monomer or the dimer CL4 may act by blocking
the receptor activation via inhibition of either EGFR homodimers
and heterodimers with cognate ErbB2 or ErbB3, thus irrespective
of the ligand that causes receptors dimerization. Indeed, treatment
of EGFR-positive cancer cells with CL4 strongly inhibits both the
EGF-induced tyrosine phosphorylation of EGFR and ErbB2 and
the Hrg-dependent tyrosine phosphorylation of EGFR and ErbB3.
In all cases, inhibition is mediated by specific recognition of EGFR
since CL4 has no effect on EGFR-negative cells.
The mitogen-activated protein kinase pathway is a major
downstream signaling route of the EGFR/ErbB family and is an
invariable target of all ErbB ligands [3,4]. Consistently, in A549 and
Calu1 cells, expressing both EGFR and ErbB3, CL4 strongly
reduces phospho-ERK 1/2 induced by either EGF or Hrg
stimulation. Conversely, a strong reduction of AKT activation
following CL4-treatment was observed in the presence of Hrg
stimulation of the cells but not of EGF stimulation i.e. when EGFR
activation proceeds essentially through dimerization of EGFR with
ErbB3. It is reported that PI3K couples directly with ErbB3 but
indirectly with EGFR via Gab1 since PI3K docking sites are absent
onEGFR and ErbB2, whereas, six sites arepresent onErbB3 [2,30].
This means that the EGFR-dependent activation of PI3K occurs
mainly through dimerization of EGFR with ErbB3. Accordingly, a
recent computationalmodel of the ErbB signaling networkidentified
ErbB3 as the key node in ligand-induced activation of the ErbB
receptor-PI3K axis [24]. Thus, the CL4 ability to inhibit phospho-
AKTonlywheninducedbyHrgbutnotEGF,couldbeexplainedby
an aptamer preferential inhibition of EGFR-EGFR with respect to
EGFR-ErbB3 complexes induced by EGF stimulation.
The selective induction of cell death in cancer treatment is the
goal of new therapeutic strategies. We found that, as a consequence
of the EGFR inhibition, CL4 strongly inhibits the anti-apoptotic
STAT3 and induces cell death selectively in EGFR-positive cancer
cells by activation of caspase-3, caspase-8 and PARP. Notably, CL4
37uC, on A549 cells. In (B–E), the results are expressed relative to the background binding detected with the CL4sc used as a negative control. Error
bars depict means 6 s.d. (n=3). (F) Lysates from A549 cells untreated (lane 1) or treated with biotinylated CL4sc (CL4sc-bio, lane 2) or CL4 (CL4-bio,
lane 3) were purified on streptavidin beads and immunoblotted with anti-EGFR antibodies. Lane 4, 10 mg-cell lysates. In (A, C, F), molecular weights of
indicated proteins are reported.
doi:10.1371/journal.pone.0024071.g002
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inhibits tumor growth up to 16-days treatment as assessed by tumor
volumes. It is noteworthy that CL4 is protected from rapid nuclease
degradation bythe29-FPymodification thusincreasing its half-lifein
vivo of several hours. Further it has been shown that this modification
renders aptamers even less immunogenic than natural RNA [31].
Five EGFR inhibitors, two monoclonal antibodies (cetuximab,
panitumumab) and three TKIs (erlotinib, gefitinib and lapatinib),
have recently gained FDA approval in oncology. Despite clinical
success, patients who initially respond to EGFR inhibitors may
subsequently become refractory [10,11], thus the attention has been
directedtowardsalternative strategies,includingtheuseofcombined
therapeutic protocols [10,11]. Interestingly, CL4 strongly induces
apoptosisof cancercelllines thatareresistant tothose concentrations
of gefitinib and cetuximab that reflect the mean steady-state plasma
concentrations at the FDA-approved dosing level [32]. Further, the
Figure 3. CL4 inhibits EGF-dependent EGFR activation. (A) Serum starved A549 cells (150,000 cells per 3.5-cm plate) were either left untreated
or treated for 3 h with 200 nM CL4 or CL4sc and then stimulated for the indicated times with EGF (50 ng/ml) alone or in the presence of each
aptamer. Cell lysates were immunoblotted with anti-(phospho)-EGFR (pEGFR), anti-EGFR, anti-(phospho)-ERK1/2 (pERK), anti-(phospho)-STAT3
(pSTAT3), anti-(phospho)-AKT (pAKT) antibodies, as indicated. (B,C) Calu 1 and A431 cells were treated as in (A) and cell lysates were immunoblotted
with anti-pEGFR, anti-EGFR and anti-pSTAT3 antibodies, as indicated. In (A–C), atubulin was used as an internal control. Values below the blots
indicate signal levels relative to 5 min-EGF stimulated control, arbitrarily set to 1 (labeled with asterisk). (D Lysates from SKBr3 cells treated as in (A),
were immunoprecipitated with anti-(phospho)-tyrosine (pTyr) antibodies and immunoblotted with anti-ErbB2 and anti-EGFR antibodies, as indicated.
Values below the blots indicate signal levels relative to 5 min-EGF stimulated CL4sc control, arbitrarily set to 1 (labeled with asterisk). In (A–D),
molecular weights of indicated proteins are reported, ‘‘C’’ indicates mock-treated cells. Quantitation was done as in Figure 2. Blots shown are
representative of at least four independent experiments.
doi:10.1371/journal.pone.0024071.g003
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cell viability more effectively than the treatment with each single
inhibitor, thus showing additive interactions.
Most importantly, CL4 and cetuximab show a clear synergy
when used in combination in the treatment of A549 tumors in vivo
as revealed by histological examination of the tumor sections for
proliferating and apoptotic cells staining. Whether the epitopes
recognized by the monoclonal antibody and the aptamer overlap
remain to be ascertained.
Recently, RNA-aptamers have been selected against the
purified ectodomain of EGFR [18,19,20]. No similarity of
sequence exists between CL4 and these anti-EGFR aptamers.
Further, despite they are high affinity ligands for EC-EGFR (Kd
values in the range of 2–7 nM), no in vivo functional effect has been
associated to the above aptamers.
In conclusion, the inhibitory properties of CL4 demonstrate its
potential usefulness as a lead compound for the design of a new class
of anticancer drugs and may become a valuable addition to the
repertoire of inhibitors that target cancers that overexpress EGFR.
Materials and Methods
Ethics Statement
All the experimental procedures were approved by the Ethical
Committee for the Animal Use (CESA) of the Istituto di Ricerche
Genetiche Gaetano Salvatore (IRGS) and where communicated to
the national authorities accordingly with national and European
rules (permit number 1519).
Cells and shRNA transfection
Growth conditions for human cell lines used (American Type
Culture Collection) were previously reported: NSCLC A549,
H460 and Calu1 [33], glioma U87MG and T98G [34], breast
MCF7, SKBr3 and T47D [35]. NIH3T3 and NIH/EGFR are
previously described [36].
For EGFR gene silencing, A549 (350,000 cells per 6 cm plate)
were transfected with 6 mg of shRNAEGFR or shRNActrl (Open
Biosystems) and Lipofectamine 2000 (Invitrogen).
Immunoblot analysis
Immunoprecipitation and immunoblotting were performed as
described [37]. The primary antibodies used were: anti-phospho-
EGFR (Tyr1062), anti-ErbB3, anti-phospho-ErbB3 (Tyr1222),
anti-ErbB2, anti-phospho-ERK1/2 (E10), anti-phospho-AKT
(Ser473), anti-phospho-AKT (Thr308), anti-AKT, anti-phospho-
STAT3 (Tyr705), anti-caspase-3, anti-caspase-8 (1C12) and anti-
PARP, anti-cleaved Caspase-8 (18C8) (Cell Signaling); anti-ERK1
(C-16), anti-EGFR, anti-ErbB3 (C-17), anti-ErbB4 (C-18) (Santa
Cruz Biotechnology); anti-phospho-tyrosine (4G10, Upstate Bio-
technology Incorporated); anti-a tubulin (DM 1A) (Sigma). RTK
antibody arrays (R&D Systems) were performed as recommended.
For ligand-dependent EGFR activation EGF and Hrg1b1
(indicated as Hrg), both from R&D Systems, were used.
Figure 4. CL4 inhibits Hrg-dependent EGFR activation. (A,B) Serum starved A549 and Calu1 cells (150,000 cells per 3.5-cm plate) were either
left untreated or treated for 3 h with 200 nM CL4 or CL4sc and then stimulated for 5 min with Hrg (100 ng/ml) alone or in the presence of each
aptamer. Cell lysates were immunoblotted with anti-(phospho)-ErbB3 (pErbB3), anti-ErbB3, anti-pEGFR, anti-EGFR, anti-pERK, anti-ERK, anti-pAKT and
anti-AKT antibodies, as indicated. Values below the blots indicate signal levels relative to Hrg stimulated control, arbitrarily set to 1 (labeled with
asterisk). Molecular weights of indicated proteins are reported, ‘‘C’’ indicates mock-treated cells. Quantitation was done as in Figure 2. Blots shown are
representative of at least four independent experiments.
doi:10.1371/journal.pone.0024071.g004
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24071Figure 5. CL4 induces apoptosis. (A) A549 and H460 cells (5,000 cells/well in 96-well plates) were either left untreated or treated for 24 h and 48 h
with 3 mM CL4 or CL4sc, renewing treatment each 24 h and the percentage of apoptotic cells (sub-G1 peak) was determined by FACS following PI
incorporation. (B,C) A549 were left untreated or treated with 200 nM-final concentration of CL4 or CL4sc for the indicated incubation times (B) or for
6 h with increasing amounts of each aptamer (C) and cell lysates were analyzed by caspase-3 activation fluorimetric assay. (D) Lysates from A549 cells
left untreated or treated for 6 h with 200 nM of indicated aptamers or 200 ng/ml TRAIL were immunoblotted with anti-caspase-3, anti-PARP and anti-
atubulin antibodies, as indicated. (E,F) Cell lysates as in (D) were analyzed by caspase-8 and caspase-9 activation fluorimetric assays (E) or by
immunoblotting with anti-caspase-8 and anti-atubulin antibodies, as indicated (F). In (D,F), ‘‘C’’ indicates mock-treated cells. Blots shown are
representative of at least three independent experiments. Molecular weights of full-length and cleaved caspase-3, 8 and PARP are reported. In (A–
C,E), error bars depict means 6 s.d. (n=3).
doi:10.1371/journal.pone.0024071.g005
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PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24071Cell viability assay and FACS analysis
Cell viability was assessed with CellTiter 96H AQueous One
Solution cell Proliferation Assay (Promega) as recommended. To
assess apoptosis, cells were stained with 2 mg/ml propidium iodide
(PI, Sigma) for 30 min at 4uC and analyzed by FACS. For
combined treatment with CL4, we used TRAIL (Alexis Biochem-
icals), paclytaxel, cisplatin (Sigma) and gefitinib (LC laboratories).
Caspases 3, 8 and 9 activity measurement
50 mg-cell lysates were incubated at 37uC for 1 h with substrate
of caspase-3 (Ac-DEVD-AFC), caspase-8 (Ac-IETD-AFC) or
caspase-9 (Ac-LEHD-AFC) (Alexis Bichemicals) and the fluores-
cence from cleaved substrate was measured.
Whole-cell SELEX and aptamers
A library of 29F-Py RNAs containing a central stretch of 45
random nucleotides was subjected to a differential SELEX
protocol against NSCLC. At each round, the positive selection
step on A549 cells was preceded by one or two counterselection
steps against H460 cells and the SELEX cycle was performed as
described [34] .
CL4 and CL4sc, the scrambled sequence of CL4, were
purchased from Sigma:
CL4: 59 GCCUUAGUAACGUGCUUUGAUGUC-
GAUUCGACAGGAGGC 39
CL4sc: 59UUCGUACCGGGUAGGUUGGCUUG-
CACAUAGAACGUGUCA 39
Before each treatment, the aptamers were subjected to a short
denaturation-renaturation step (85uC for 5 min, snap-cooled on
ice for 2 min, and allowed to warm up to 37uC). For cell treatment
longer than 6 h, RNA concentrations were determined to ensure
the continuous presence of at least 200 nM-concentration taking
into account the 6 h-half life of the aptamer in 10% serum.
Aptamer binding analysis
Binding of CL4 or CL4sc to cells was performed as described
[34]. Filter binding analysis with the soluble extracellular domain
of human EGFR and ErbB3 as targets (R&D Systems), was
assessed by incubating 1 nM of radiolabeled aptamers with 1, 3.2,
10, 32, 100, 320 and 1000 nM of EC-EGFR or EC-ErbB3 for
15 min at 37uC in PBS supplemented with 0.01% bovine serum
albumin. EC-EGFR and EC-ErbB3 are disulfide-linked homodi-
mers; to assess the CL4 binding to the monomeric recombinant
proteins, analysis was performed in the presence of 5 mM DTT.
CL4-mediated affinity purification
CL4 or CL4sc were 39-end biotinylated by terminal transferase
and Biotin-ddUTP (Roche) and incubated in serum free culture
medium at a 200 nM-final concentration on A549 cells for 30 min
at RT. Cells were washed with PBS and lysed with 10 mM Tris-
HCl pH 7.5 containing 200 mM NaCl, 5 mM EDTA, 0.1%
Triton X-100, and protease inhibitors. 400 mg-cell extract was
incubated with 200 ml-streptavidin beads (Pierce) in 0.4 ml lysis
buffer at RT for 1 h with rotation. Following four washes with
PBS, bound proteins were recovered with Laemmli buffer and
analyzed by immunoblotting with anti-EGFR antibody.
[
3H]-Thymidine incorporation assay
A549 cells were treated for 24 h or 48 h with CL4 or CL4sc.
During the final 6 h, cells were pulsed with 1 mCi/ml [
3H]-
thymidine (45 Ci/mmol) (Amersham-Pharmacia Biosciences) added
in complete growth medium and incubated at 37uC. At the end of
each pulse, cells were harvested and [
3H]-thymidine incorporation
was analyzed by a Beckman LS 1701 Liquid Scintillation Counter.
In vivo experiments
Athymic CD-1 nude mice (nu/nu) were housed in a highly
controlled microbiological environment, thus to guarantee specific
pathogen free conditions. Mice were injected subcutaneously with
3610
6 (in 100 ml) in vitro propagated A549. Sixteen non-necrotic
tumors of about 0.5 cm in diameter were randomly divided into
two groups of eight mice as follows: group 1, CL4sc-treated; group
2, CL4-treated. Aptamers (200 pmols/injection) were injected
intratumorally in 100-ml volumes three times a week for 16 days.
During the study mice were daily monitored to avoid any sign of
suffering. Tumors were measured every 2 days with calipers and
tumor volume was calculated as follows: VT=(WXLXH)60.5236
(W, the shortest dimension; L, the longest dimension; H, the
intermediate dimension). For combined treatment of CL4 and
cetuximab, 24 non-necrotic tumors of about 0.5 cm in diameter
were randomly divided into four groups of six mice as follows:
group 1, CL4sc (200 pmols/intratumor injection three times a
week for 21 days); group 2, CL4sc plus cetuximab (200 pmols/
intratumor injection three times a week for 21 days, plus 25 mg
cetuximab/intraperitoneal injection in 100-ml volumes once a
week for the last 14 days); group 3, CL4 (200 pmols/intratumor
injection three times a week for 21 days); group 4, CL4 plus
cetuximab (200 pmols/intratumor injection three times a week for
21 days, plus 25 mg cetuximab/intraperitoneal injection in 100-ml
volumes once a week for the last 14 days).
Histology and immuno-histochemistry
Tumors were embedded in paraffin and sectioned at 6 mm. To
inhibit the endogenous peroxidases, the sections were treated with
0.5% H2O2 in absolute methanol for 15 min at RT. For
histological examinations, serial paraffin sections were stained
with Harris hematoxylin and aqueous eosin (H&E, BDH
Laboratory Supplies).
Figure 6. CL4 inhibits tumor growth. (A) A549 cells (2,000 cells/well in 24-well plates) were treated for 24 h or 48 h with CL4 or CL4sc (200 nM-
final concentration) and proliferation was determined by [
3H]-thymidine incorporation. Vertical bars indicate the standard deviation values. (B)
Growth inhibition of tumors in a mouse xenograft model bearing EGFR-positive A549 cells upon CL4 treatment (57% at 16 days compared to CL4sc
control group, P,0.01 by Mann-Whitney test). Day 0 marks the first day of injection. Data are shown as means 6 s.e.m. (n=8 tumors). (C) Three
tumors per group selected randomly were excised, lysed, and the pooled lysates were immunoblotted with anti-pEGFR, anti-EGFR, anti-caspase-3,
anti-cleaved caspase-8 and anti-atubulin antibodies, as indicated. Molecular weights of indicated proteins are reported. (D) Cell lysates as in (C) were
analyzed by caspase-3 fluorimetric assays. (E) A549 cells (4,000 cells/well in 96-well plates) were left untreated or treated for 24 h with CL4sc (200 nM-
final concentration) or CL4 (100 and 200 nM-final concentration) alone or in combination with 1 mM cetuximab or 1 mM gefitinib. Cell viability was
analyzed as reported in Methods and was expressed as percent of viable treated cells with respect to control untreated cells (indicated with ‘‘C’’).
Error bars depict means 6 s.d. (n=4). (F) Representative sections of tumors from the CL4sc, CL4sc plus cetuximab, CL4, and CL4 plus cetuximab
groups (see ‘‘Materials and Methods’’ for details) stained with H&E, Ki-67 antibody and TUNEL, as indicated. DAPI counterstaining of the boxed
regions is shown. Note reduction in cell density in the CL4-treated section stained with H&E. Magnification, 206for H&E and Ki-67 and 406for TUNEL
and DAPI. (G) Percentage of TUNEL
+/DAPI
+ cells, values represent mean 6 s.d. for 10 randomly selected fields.
doi:10.1371/journal.pone.0024071.g006
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The anti-human Ki-67 antibody (Epitomics) was 1:500 diluted and
immunostaining was done using the immunoperoxidase system of
the ‘‘Vectastain ABC kit’’ (Vector) and the ‘‘DAB substrate kit for
peroxidise’’ (Vector), according with the manufacturer’s protocol.
TUNEL assay
Apoptotic cell death in paraffin tumor tissue sections was
detected using TUNEL staining. Sections were permeabilized with
0.1% Triton X-100, 0.1% sodium citrate solution and apoptosis
was detected with in situ Cell Death fluorescein kit (Roche)
according to manufacturer’s procedure. All staining were finally
counterstained with DAPI before mounting. Microscopy and
imaging were performed in a Zeiss AxionPlan II epifluorescence
(FluoArc) Microscope. The images were processed using Axion
Vision software and edited by Image J software.
Statistical analyses
We performed statistical analyses with GraphPad Prism.
Supporting Information
Figure S1 CL4 inhibits serum-dependent EGFR and
ErbB3 phosphorylation. A549 cells were serum starved for
18 h and then stimulated with culture medium supplemented with
20% FBS for 10 min in the presence of 200 nM CL4 or CL4sc and
cell extracts were prepared. (A) 200 mg-lysates were incubated on
RTK antibody arrays. Phosphorylation levels were determined by
subsequent incubation with anti-phosphotyrosine horseradish perox-
idase. The pixel intensity associated to the phosphorylation status of
EGFR, ErbB2, ErbB3 and ErbB4, is reported. Quantitation was
done as in Figure 2 and error bars depict means 6s.d. (n=4). (B) Cell
lysateswereimmunoblotted withanti-pEGFR, anti-pErbB3 and anti-
atubulin antibodies, as indicated. Values below the blots indicate
signal levels relative to stimulated CL4sc control, arbitrarily set to 1
(labeled with asterisk). Quantitation was done as in Figure 2. Blots
shown are representative of at least two independent experiments.
(EPS)
Figure S2 CL4 binds different EGFR-positive cancer cell
lines. (A,C) Lysates from the indicated cell lines were immuno-
blotted with anti-EGFR, anti-ErbB2, anti-ErbB3 and anti-ErbB4
antibodies, as indicated. atubulin was used as an internal control.
Blots shown are representative of at least three independent
experiments. (B,D) Binding of radiolabeled CL4 (100 and 200 nM)
on the indicated cell lines. The results are expressed relative to the
background binding detected with CL4sc used as a negative
control. Error bars depict means 6 s.d. (n=3).
(EPS)
Figure S3 CL4 inhibits cell viability in EGFR-positive
cancer cell lines. (A) Indicated cell lines (4,000 cells/well in 96-
well plates) were left untreated or treated for 24 h with CL4 or
CL4sc (200 nM-final concentration) and cell viability was
analyzed as reported in Methods and expressed as percent of
viable treated cells with respect to control untreated cells (indicated
with ‘‘C’’). Error bars depict means 6 s.d. (n=4). (B) A549 cells
were left untreated or treated for 24 h with CL4 or CL4sc
(200 nM-final concentration) alone or in combination with
TRAIL, cisplatin and paclytaxel at the indicated concentrations.
Cell viability was analyzed as in (A), error bars depict means 6 s.d.
(n=4).
(EPS)
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